Advanced Biomed Inc. Common Stock

NASDAQ: ADVB · Healthcare · Medical - Diagnostics & Research

PublicHQ New York City, NY · New YorkCIK 0001941029Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 35DQ —GM —SS 32

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, return on assets · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$3.3M

Employees

as of 2026-08-23

Market cap

$11.3M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$3.3M-$3.3M2025

Total assets$6.5M$6.5M2025

Liabilities$3.0M$3.0M2025

Equity$3.5M$3.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Advanced Biomed Inc. Common Stock’s financial profile?

Advanced Biomed Inc. Common Stock earned -$3.3M in FY2025 net income.

Peers · Healthcare

Jasper Therapeutics, Inc.——PDS Biotechnology Corporation——Conavi Medical Corp.——Medicure Inc.——Skye Bioscience, Inc.——Quince Therapeutics, Inc.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOXiaomin Chen

SectorHealthcare

IndustryMedical - Diagnostics & Research

HeadquartersNew York City, NY

ExchangeNASDAQ: ADVB

Employees31

IPO date2025-03-06

Latest filings

8-K2026-07-17 8-K2026-07-01 8-K2026-06-30 DEF 14A2026-06-04 10-Q2026-05-15 8-K2026-05-01 8-K2026-04-14 8-K2026-04-03

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.